Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi 835215, India.
Bioorg Med Chem. 2013 Oct 1;21(19):5973-82. doi: 10.1016/j.bmc.2013.07.044. Epub 2013 Aug 2.
A series of 4,5,6,7-tetrabromo-1,3-dioxoisoindolin-2-yl benzenesulfonamide derivatives (compounds 1-8) was synthesized by reaction of benzene sulfonamide derivatives with 4,5,6,7-tetrabromophthalic anhydride moiety. These new sulfonamides were investigated as inhibitors of the zinc metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) and more specifically against the human (h) cytosolic isoforms hCA I, II and VII and the transmembrane tumor-associated isoform hCA IX and XII. The new compounds were good hCA I inhibitors (Kis in the range of 143 to >10,000nM), but were moderately effective, as hCA II inhibitors (Kis of 47-190nM) and poor hCA VII inhibitors (Kis in the range of 54-175nM) compared to acetazolamide. The tumor-associated hCA IX was effectively inhibited with Kis ranging between 8.5 and 234nM and hCA XII with inhibition constants in the range of 6.1-197nM with high selectivity ratio. The structure-activity relationship (SAR) with this series of sulfonamides is straightforward, with the main features leading to good activity for each isoforms being established. The high sequence hCA alignment homology and molecular docking study of compounds was performed to rationalize the SAR reported over here.
一系列 4,5,6,7-四溴-1,3-二氧代异吲哚啉-2-基苯磺酰胺衍生物(化合物 1-8)通过苯磺酰胺衍生物与 4,5,6,7-四溴邻苯二甲酸酐部分的反应合成。这些新的磺酰胺被研究为锌金属酶碳酸酐酶(CA,EC 4.2.1.1)的抑制剂,特别是针对人(h)胞质同工酶 hCA I、II 和 VII 以及跨膜肿瘤相关同工酶 hCA IX 和 XII。新化合物是良好的 hCA I 抑制剂(Ki 值范围为 143 到>10,000nM),但与乙酰唑胺相比,对 hCA II 的抑制效果中等(Ki 值为 47-190nM),对 hCA VII 的抑制效果较差(Ki 值范围为 54-175nM)。肿瘤相关 hCA IX 的 Ki 值在 8.5 到 234nM 之间,hCA XII 的 Ki 值在 6.1 到 197nM 之间,具有较高的选择性比值,被有效抑制。该系列磺酰胺的构效关系(SAR)非常直接,确定了导致每种同工酶具有良好活性的主要特征。对化合物进行了高序列 hCA 同源性和分子对接研究,以合理化此处报道的 SAR。